title: Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE.
abstract: OBJECTIVE
  We measured bowel function and bowel bother longitudinally the first 2 years after treatment for early stage prostate cancer.
  
  
  METHODS
  We studied bowel function and bother in 1,584 men recently diagnosed with early stage prostate cancer and followed for 2 years after radical prostatectomy, external beam radiation or brachytherapy. Principal outcomes were assessed with the UCLA Prostate Cancer Index, a validated instrument that includes these 2 domains. Multivariate analyses were conducted to ascertain significant predictors of bowel function and bother. Subjects were drawn from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE, TAP Pharmaceutical Products, Inc., Lake Forest, Illinois), a national, longitudinal registry of men with prostate cancer.
  
  
  RESULTS
  Men treated with external beam radiation or brachytherapy suffered worse bowel function and were more bothered by it than men treated surgically. After an initial period of posttreatment impairment, all 3 groups demonstrated improvement with time in both domains, although bowel bother persisted longer in men treated with external beam radiation. Surgery patients reached a steady state by 3 months, while those treated with external beam radiation or brachytherapy continued to improve for more than a year after treatment. Older men were more bothered by bowel dysfunction than younger men. Ethnicity, comorbidity and education did not affect either bowel function or bother.
  
  
  CONCLUSIONS
  Patients undergoing surgery, external beam radiation or brachytherapy have different longitudinal profiles of bowel function and bother during the first 2 years after treatment. Bowel function and bother are worse after external beam radiation but they are also impaired after brachytherapy. Men choosing surgery experience transient impairment in the bowel domains. This information may be useful to patients making treatment decisions for early stage prostate cancer.
authors.affiliation: Department of Urology, David Geffen School of Medicine, University of California, Los Angeles 90095-1738, USA. mlitwin@ucla.edu
authors.forename: Mark S
authors.initials: MS
authors.lastname: Litwin
authors.forename: Natalia
authors.initials: N
authors.lastname: Sadetsky
authors.forename: David J
authors.initials: DJ
authors.lastname: Pasta
authors.forename: Deborah P
authors.initials: DP
authors.lastname: Lubeck
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy* / Q000601:surgery*; D000368:Aged; D001918:Brachytherapy; D015897:Comorbidity; D003672:Defecation; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011184:Postoperative Period; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery*; D011788:Quality of Life